Gastrointestinal Malignancies

Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer

Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer

By

In this study, the impact of advancements in surgical technique and systemic therapy for stage II and III rectal cancers was assessed via a comparison of outcomes after neoadjuvant chemoradiotherapy followed by definitive resection with those for neoadjuvant multiagent chemotherapy without radiation therapy.

Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score

Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score

By

In patients with advanced HCC and a baseline αFP level of 400 ng/mL or more, a survival benefit with second-line ramucirumab therapy was observed for those with Child-Pugh scores of 5 and 6.

Adding Bevacizumab to Adjuvant Capecitabine Not Effective for mCRC

By

The combination of adjuvant bevacizumab and capecitabine failed to improve disease-free survival compared with capecitabine alone in patients with mCRC who had undergone potentially curative surgery.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs